205 related articles for article (PubMed ID: 34655447)
1. ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology.
Ortega-Muelas M; Roche O; Fernández-Aroca DM; Encinar JA; Albandea-Rodríguez D; Arconada-Luque E; Pascual-Serra R; Muñoz I; Sánchez-Pérez I; Belandia B; Ruiz-Hidalgo MJ; Sánchez-Prieto R
J Cell Mol Med; 2021 Nov; 25(22):10591-10603. PubMed ID: 34655447
[TBL] [Abstract][Full Text] [Related]
2. Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation.
Simões AE; Pereira DM; Gomes SE; Brito H; Carvalho T; French A; Castro RE; Steer CJ; Thibodeau SN; Rodrigues CM; Borralho PM
Cell Death Dis; 2015 Apr; 6(4):e1718. PubMed ID: 25855966
[TBL] [Abstract][Full Text] [Related]
3. HB-EGF induces cardiomyocyte hypertrophy via an ERK5-MEF2A-COX2 signaling pathway.
Lee KS; Park JH; Lim HJ; Park HY
Cell Signal; 2011 Jul; 23(7):1100-9. PubMed ID: 21244855
[TBL] [Abstract][Full Text] [Related]
4. MEK5 and ERK5 are localized in the nuclei of resting as well as stimulated cells, while MEKK2 translocates from the cytosol to the nucleus upon stimulation.
Raviv Z; Kalie E; Seger R
J Cell Sci; 2004 Apr; 117(Pt 9):1773-84. PubMed ID: 15075238
[TBL] [Abstract][Full Text] [Related]
5. ERK5 signalling in prostate cancer promotes an invasive phenotype.
Ramsay AK; McCracken SR; Soofi M; Fleming J; Yu AX; Ahmad I; Morland R; Machesky L; Nixon C; Edwards DR; Nuttall RK; Seywright M; Marquez R; Keller E; Leung HY
Br J Cancer; 2011 Feb; 104(4):664-72. PubMed ID: 21266977
[TBL] [Abstract][Full Text] [Related]
6. ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells.
Sarközi R; Miller B; Pollack V; Feifel E; Mayer G; Sorokin A; Schramek H
J Cell Physiol; 2007 Apr; 211(1):88-100. PubMed ID: 17131384
[TBL] [Abstract][Full Text] [Related]
7. The MEK5/ERK5 signalling pathway in cancer: a promising novel therapeutic target.
Simões AE; Rodrigues CM; Borralho PM
Drug Discov Today; 2016 Oct; 21(10):1654-1663. PubMed ID: 27320690
[TBL] [Abstract][Full Text] [Related]
8. Identification of benzimidazole-based inhibitors of the mitogen activated kinase-5 signaling pathway.
Flaherty PT; Chopra I; Jain P; Yi S; Allen E; Cavanaugh J
Bioorg Med Chem Lett; 2010 May; 20(9):2892-6. PubMed ID: 20382528
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
Wright TD; Raybuck C; Bhatt A; Monlish D; Chakrabarty S; Wendekier K; Gartland N; Gupta M; Burow ME; Flaherty PT; Cavanaugh JE
J Cell Biochem; 2020 Feb; 121(2):1156-1168. PubMed ID: 31464004
[TBL] [Abstract][Full Text] [Related]
10. Activation of cytosolic phospholipase A2alpha by epidermal growth factor (EGF) and phorbol ester in HeLa cells: different effects of inhibitors for EGF receptor, protein kinase C, Src, and C-Raf.
Matsuzawa Y; Kiuchi Y; Toyomura K; Matsumoto I; Nakamura H; Fujino H; Murayama T; Kawashima T
J Pharmacol Sci; 2009 Oct; 111(2):182-92. PubMed ID: 19783865
[TBL] [Abstract][Full Text] [Related]
11. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones.
Deng X; Elkins JM; Zhang J; Yang Q; Erazo T; Gomez N; Choi HG; Wang J; Dzamko N; Lee JD; Sim T; Kim N; Alessi DR; Lizcano JM; Knapp S; Gray NS
Eur J Med Chem; 2013; 70():758-67. PubMed ID: 24239623
[TBL] [Abstract][Full Text] [Related]
12. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
13. Design of a dual ERK5 kinase activation and autophosphorylation inhibitor to block cancer stem cell activity.
Kedika SR; Shukla SP; Udugamasooriya DG
Bioorg Med Chem Lett; 2020 Dec; 30(23):127552. PubMed ID: 32946922
[TBL] [Abstract][Full Text] [Related]
14. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
[TBL] [Abstract][Full Text] [Related]
15. Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion.
Serrano-Oviedo L; Ortega-Muelas M; García-Cano J; Valero ML; Cimas FJ; Pascual-Serra R; Fernandez-Aroca DM; Roche O; Ruiz-Hidalgo MJ; Belandia B; Giménez-Bachs JM; Salinas AS; Sanchez-Prieto R
PLoS One; 2018; 13(7):e0200878. PubMed ID: 30048489
[TBL] [Abstract][Full Text] [Related]
16. Identification of pharmacological inhibitors of the MEK5/ERK5 pathway.
Tatake RJ; O'Neill MM; Kennedy CA; Wayne AL; Jakes S; Wu D; Kugler SZ; Kashem MA; Kaplita P; Snow RJ
Biochem Biophys Res Commun; 2008 Dec; 377(1):120-5. PubMed ID: 18834865
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships of benzimidazole-based selective inhibitors of the mitogen activated kinase-5 signaling pathway.
Flaherty PT; Chopra I; Jain P; Monlish D; Cavanaugh J
Bioorg Med Chem; 2010 Nov; 18(22):8054-60. PubMed ID: 20965737
[TBL] [Abstract][Full Text] [Related]
18. Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton.
Barros JC; Marshall CJ
J Cell Sci; 2005 Apr; 118(Pt 8):1663-71. PubMed ID: 15797923
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic signaling of MEK5-ERK5.
Hoang VT; Yan TJ; Cavanaugh JE; Flaherty PT; Beckman BS; Burow ME
Cancer Lett; 2017 Apr; 392():51-59. PubMed ID: 28153789
[TBL] [Abstract][Full Text] [Related]
20. ERK5 and its role in tumour development.
Lochhead PA; Gilley R; Cook SJ
Biochem Soc Trans; 2012 Feb; 40(1):251-6. PubMed ID: 22260700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
